Trial Profile
Phase I Randomised Multi-Centre Study to Demonstrate the Safety of WBRT Concomitant to Intrathecal Liposomal Cytarabine (DepoCyte) Versus WBRT & Sequential Intrathecal Liposomal Cytarabine (DepoCyte) for Treatment of STNM With or Without Brain Metastasis.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 22 Feb 2013
Price :
$35
*
At a glance
- Drugs Cytarabine (Primary)
- Indications Meningeal carcinomatosis
- Focus Adverse reactions
- Sponsors Mundipharma International
- 23 Oct 2012 Planned End Date changed from 1 Feb 2012 to 1 Mar 2013 as reported by ClinicalTrials.gov.
- 01 Oct 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 03 Feb 2011 Trial location (Austria) identified as reported by ClinicalTrials.gov.